Literature DB >> 31646346

mGlu5 in GABAergic neurons modulates spontaneous and psychostimulant-induced locomotor activity.

Chia-Shan Wu1,2,3, Christopher P Jew4,5,6, Hao Sun4,5, Carlos J Ballester Rosado4,5,6, Hui-Chen Lu7,8,9,10.   

Abstract

RATIONALE: A role of group I metabotropic glutamate receptor 5 (mGlu5) in regulating spontaneous locomotion and psychostimulant-induced hyperactivity has been proposed.
OBJECTIVES: This study aims to determine if mGlu5 in GABAergic neurons regulates spontaneous or psychostimulant-induced locomotion.
METHODS: We generated mice specifically lacking mGlu5 in forebrain GABAergic neuron by crossing DLX-Cre mice with mGlu5flox/flox mice to generate DLX-mGlu5 KO mice. The locomotion of adult mice was examined in the open-field assay (OFA) and home cage setting. The effects of the mGlu5 antagonist 6-methyl-2-(phenylethynyl)pyridine (MPEP), cocaine, and methylphenidate on acute motor behaviors in DLX-mGlu5 KO and littermate control mice were assessed in OFA. Striatal synaptic plasticity of these mice was examined with field potential electrophysiological recordings.
RESULTS: Deleting mGlu5 from forebrain GABAergic neurons results in failure to induce long-term depression (LTD) in the dorsal striatum and absence of habituated locomotion in both novel and familiar settings. In a familiar environment (home cage), DLX-mGlu5 KO mice were hyperactive. In the OFA, DLX-mGlu5 KO mice exhibited initial hypo-activity, and then gradually increased their locomotion with time, resulting in no habituation response. DLX-mGlu5 KO mice exhibited almost no locomotor response to MPEP (40 mg/kg), while the same dose elicited hyperlocomotion in control mice. The DLX-mGlu5 KO mice also showed reduced hyperactivity response to cocaine, while they retained normal hyperactivity response to methylphenidate, albeit with delayed onset.
CONCLUSION: mGlu5 in forebrain GABAergic neurons is critical to trigger habituation upon the initiation of locomotion as well as to mediate MPEP-induced hyperlocomotion and modulate psychostimulant-induced hyperactivity.

Entities:  

Keywords:  GABAergic; Habituation; Hyperactivity; Locomotion; Metabotropic receptors; Psychostimulant

Mesh:

Substances:

Year:  2019        PMID: 31646346      PMCID: PMC7024012          DOI: 10.1007/s00213-019-05367-0

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  118 in total

1.  Extinction training after cocaine self-administration induces glutamatergic plasticity to inhibit cocaine seeking.

Authors:  Lori A Knackstedt; Khaled Moussawi; Ryan Lalumiere; Marek Schwendt; Matthias Klugmann; Peter W Kalivas
Journal:  J Neurosci       Date:  2010-06-09       Impact factor: 6.167

2.  Lesions of dorsolateral striatum preserve outcome expectancy but disrupt habit formation in instrumental learning.

Authors:  Henry H Yin; Barbara J Knowlton; Bernard W Balleine
Journal:  Eur J Neurosci       Date:  2004-01       Impact factor: 3.386

Review 3.  The pharmacology of cocaine related to its abuse.

Authors:  C E Johanson; M W Fischman
Journal:  Pharmacol Rev       Date:  1989-03       Impact factor: 25.468

4.  Genome-wide association study in German patients with attention deficit/hyperactivity disorder.

Authors:  Anke Hinney; André Scherag; Ivonne Jarick; Özgür Albayrak; Carolin Pütter; Sonali Pechlivanis; Maria R Dauvermann; Sebastian Beck; Heike Weber; Susann Scherag; Trang T Nguyen; Anna-Lena Volckmar; Nadja Knoll; Stephen V Faraone; Benjamin M Neale; Barbara Franke; Sven Cichon; Per Hoffmann; Markus M Nöthen; Stefan Schreiber; Karl-Heinz Jöckel; H-Erich Wichmann; Christine Freitag; Thomas Lempp; Jobst Meyer; Susanne Gilsbach; Beate Herpertz-Dahlmann; Judith Sinzig; Gerd Lehmkuhl; Tobias J Renner; Andreas Warnke; Marcel Romanos; Klaus-Peter Lesch; Andreas Reif; Benno G Schimmelmann; Johannes Hebebrand
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2011-10-19       Impact factor: 3.568

Review 5.  Metabotropic glutamate receptors as drug targets: what's new?

Authors:  Ferdinando Nicoletti; Valeria Bruno; Richard Teke Ngomba; Roberto Gradini; Giuseppe Battaglia
Journal:  Curr Opin Pharmacol       Date:  2014-12-12       Impact factor: 5.547

6.  The activation of metabotropic glutamate 5 receptors in the rat ventral tegmental area increases dopamine extracellular levels.

Authors:  Carla Ferrada; Ramón Sotomayor-Zárate; Jorge Abarca; Katia Gysling
Journal:  Neuroreport       Date:  2017-01-01       Impact factor: 1.837

7.  Effect of methylphenidate on attention in children with attention deficit hyperactivity disorder (ADHD): ERP evidence.

Authors:  G A Sunohara; M A Malone; J Rovet; T Humphries; W Roberts; M J Taylor
Journal:  Neuropsychopharmacology       Date:  1999-08       Impact factor: 7.853

Review 8.  Modulation of striatal projection systems by dopamine.

Authors:  Charles R Gerfen; D James Surmeier
Journal:  Annu Rev Neurosci       Date:  2011       Impact factor: 12.449

Review 9.  Striatal plasticity and basal ganglia circuit function.

Authors:  Anatol C Kreitzer; Robert C Malenka
Journal:  Neuron       Date:  2008-11-26       Impact factor: 17.173

10.  Abnormalities of social interactions and home-cage behavior in a mouse model of Rett syndrome.

Authors:  Paolo Moretti; J Adriaan Bouwknecht; Ryan Teague; Richard Paylor; Huda Y Zoghbi
Journal:  Hum Mol Genet       Date:  2004-11-17       Impact factor: 6.150

View more
  2 in total

1.  Genetic disruption of Grm5 causes complex alterations in motor activity, anxiety and social behaviors.

Authors:  Jian Xu; John J Marshall; Stephen Kraniotis; Toshihiro Nomura; Yongling Zhu; Anis Contractor
Journal:  Behav Brain Res       Date:  2021-05-21       Impact factor: 3.352

2.  The glutamate metabotropic receptor 5 (GRM5) gene is associated with beef cattle home range and movement tortuosity.

Authors:  Cristian A Moreno García; Huitong Zhou; David Altimira; Robyn Dynes; Pablo Gregorini; Sadeepa Jayathunga; Thomas M R Maxwell; Jonathan Hickford
Journal:  J Anim Sci Biotechnol       Date:  2022-09-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.